Essilor International Compagnie Generale D'Optique SA (ESSI.PA)

ESSI.PA on Paris Stock Exchange

106.30EUR
27 Mar 2015
Change (% chg)

€1.70 (+1.63%)
Prev Close
€104.60
Open
€105.30
Day's High
€106.60
Day's Low
€104.95
Volume
520,178
Avg. Vol
579,428
52-wk High
€109.35
52-wk Low
€71.16

ESSI.PA

Chart for ESSI.PA

About

Essilor International Compagnie Generale D'Optique SA is a France-based ophthalmic optics company. The Company is engaged in the corrective lenses. Its brands are Varilux, Crizal, Definity, Xperio, Optifog, Kodak and Foster Grant. The Company also develops and sells equipment for prescription laboratories, particularly through... (more)

Overall

Beta: 0.22
Market Cap(Mil.): €22,949.38
Shares Outstanding(Mil.): 215.89
Dividend: 1.02
Yield (%): 0.96

Financials

  ESSI.PA Industry Sector
P/E (TTM): 24.56 41.29 40.89
EPS (TTM): 4.33 -- --
ROI: 15.47 10.74 16.10
ROE: 21.43 12.55 16.95
Search Stocks

N.America, emerging markets boost Essilor profits

PARIS, Feb 19 - Essilor, the world's largest maker of ophthalmic lenses, posted a 15 percent rise in full-year operating profit on the back of 12 percent revenue growth, helped by expansion in North America and fast-growing countries, and acquisitions.

19 Feb 2015

BRIEF-458,564 new Essilor shares to be listed on Euronext Paris - Euronext

* 458,564 new ordinary shares issued by Essilor Intl-Cie Gle Optique will be listed on Euronext Paris market as of Jan. 12

07 Jan 2015

Essilor keeps 2014 goals as third-quarter sales growth accelerates

PARIS - Essilor , the world's largest maker of ophthalmic lenses, stuck to its full-year revenue and margin forecasts after organic sales growth accelerated in the third quarter.

24 Oct 2014

UPDATE 1-Essilor keeps 2014 goals as Q3 sales growth accelerates

* Sees 2014 adj operating margin of around 18.6 pct (Adds detail, background)

24 Oct 2014

Essilor keeps 2014 goals as Q3 sales growth accelerates

PARIS, Oct 24 - Essilor, the world's largest maker of ophthalmic lenses, stuck to its full-year revenue and margin forecasts after organic sales growth accelerated in the third quarter.

24 Oct 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: ValuEngine, Inc.
$49.00
Provider: Finlabo SIM Spa
$10.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks